Welcome to our dedicated page for Resverlogix news (Ticker: RVXCF), a resource for investors and traders seeking the latest updates and insights on Resverlogix stock.
Resverlogix Corp. (RVXCF) is a clinical-stage biotechnology company pioneering epigenetic therapies for cardiovascular and chronic diseases. This page aggregates official news releases and verified updates about their lead candidate apabetalone, strategic partnerships, and clinical progress.
Investors and researchers will find timely updates on trial results, regulatory milestones, and scientific presentations. Content includes financial agreements, clinical data disclosures, and research collaborations, providing a comprehensive view of the company's trajectory in epigenetic drug development.
All materials are sourced directly from Resverlogix communications and vetted industry publications. Bookmark this page for structured access to developments about BET protein research, cardiovascular treatment innovations, and the company's unique approach to gene regulation therapies.
Resverlogix Corp. (TSX: RVX) presented at the European Society of Cardiology (ESC) Congress 2024, highlighting apabetalone's potential cardioprotective benefits. Key points include:
1. Apabetalone reduced MACE and heart failure hospitalization hazard by 63% (p=0.0002) in patients taking next-generation glucose-lowering drugs.
2. Independent researchers presented data on apabetalone's benefits for vascular dysfunction, heart failure, cellular aging, and pulmonary arterial hypertension.
3. The company positions apabetalone as a drug with potential benefits across various metabolic diseases, including cardiovascular disease, chronic kidney disease, inflammation, and diabetes.
4. Resverlogix plans to demonstrate apabetalone's efficacy in combination with SGLT2 inhibitors in the upcoming BETonMACE2 trial.
Resverlogix Corp. (TSX: RVX) held its Annual & Special Meeting of Shareholders on July 31, 2024, in Calgary, Alberta. Shareholders elected four Board members and approved all resolutions outlined in the Notice of Meeting and Management Information Circular. The voting results showed strong support for all directors, with approval rates ranging from 95.11% to 95.91%.
Additionally, Resverlogix announced the closing of a two-year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., This extension provides the company with continued financial stability. The Information Circular is available on SEDAR and the Resverlogix website, and a webcast archive of the executive presentation is accessible online.
Resverlogix Corp. (TSX: RVX) has announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., The maturity date has been extended to May 13, 2026. Key changes include:
1. Elimination of Hepalink's conversion privileges
2. Increase in interest rate from 12% to 18% per annum, effective May 14, 2024
3. Additional reporting requirements for Resverlogix
4. Continuation of normal business operations
The amendment is subject to Toronto Stock Exchange and shareholder approval. Shareholders will vote on the amendments at Resverlogix's annual and special meeting on July 31, 2024. Hepalink has agreed to forbear from enforcing the debenture, contingent on shareholder approval.
Resverlogix has rescheduled its Annual and Special Meeting of Shareholders to July 31, 2024, at 1:00 PM MT, from its original date of June 27, 2024. Shareholders will receive a Notice of Meeting and Management Information Circular detailing the matters to be discussed. These documents will also be available on SEDAR+ at www.sedarplus.ca. Following the formal business proceedings, Resverlogix will present a corporate update.
Resverlogix Corp. (TSX: RVX) announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group. The new maturity date is May 13, 2026.
Along with the extension, Hepalink's conversion privileges have been eliminated, and the interest rate has increased from 12% to 18% per annum, starting May 14, 2024. The changes are subject to execution of definitive transaction documents, customary closing conditions, and Toronto Stock Exchange approval.
CEO Donald McCaffrey expressed appreciation for Hepalink's continued support.
FAQ
What is the current stock price of Resverlogix (RVXCF)?
What is the market cap of Resverlogix (RVXCF)?
